CML is a myeloproliferative neoplasm driven by the BCR::ABL1 (breakpoint cluster region-AbLeson fusion gene) fusion tyrosine kinase, whereas CLL is a lymphoproliferative disorder of monoclonal CD5+ve B lymphocytes. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.